Soligenix
SNGX
1,65 €
Share price
-1.31%
Change (1 day)
-47.97%
Change (1 year)
Categories
Revenue for Soligenix (SNGX)
Revenue in 2025 (TTM): N/A
In 2024 the company made a revenue of €0.11 Million a decrease over the revenue in the year 2023 that were of €0.23 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Soligenix from 1998 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
2025 (TTM)  | N/A | -100% |
| 2024 | €0.11 M | -51.66% |
| 2023 | €0.23 M | -0.18% |
| 2022 | €0.23 M | 691.41% |
| 2021 | €0.02 M | -98.12% |
| 2020 | €1.56 M | -45.32% |
| 2019 | €2.87 M | -17.19% |
| 2018 | €3.46 M | -3.78% |
| 2017 | €3.6 M | -63.73% |
| 2016 | €9.93 M | 23.87% |
| 2015 | €8.01 M | 38.48% |
| 2014 | €5.79 M | 148.05% |
| 2013 | €2.33 M | -1.79% |
| 2012 | €2.37 M | -59.71% |
| 2011 | €5.9 M | 302.98% |
| 2010 | €1.46 M | -25.5% |
| 2009 | €1.96 M | 18.94% |
| 2008 | €1.65 M | 91.75% |
| 2007 | €0.86 M | -50.84% |
| 2006 | €1.75 M | -30.22% |
| 2005 | €2.51 M | |
| 1999 | €0 M | -100% |
| 1998 | €0.33 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Cleveland BioLabs
CBLI | €0.55 M | N/A | 🇺🇸 USA |
 Emergent BioSolutions
EBS | €0.81 B | N/A | 🇺🇸 USA |
 Sanofi SNY | €41.52 B | N/A | 🇫🇷 France |
 Pfizer PFE | €54.68 B | N/A | 🇺🇸 USA |
 Johnson & Johnson JNJ | €78.20 B | N/A | 🇺🇸 USA |
 Athersys ATHX | €0.07 M | N/A | 🇺🇸 USA |
 Onconova Therapeutics ONTX | €0.19 M | N/A | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | €14.54 B | N/A | 🇮🇱 Israel |